NO20090201L - Nye heteroarylsubstituerte benzoksazoler - Google Patents

Nye heteroarylsubstituerte benzoksazoler

Info

Publication number
NO20090201L
NO20090201L NO20090201A NO20090201A NO20090201L NO 20090201 L NO20090201 L NO 20090201L NO 20090201 A NO20090201 A NO 20090201A NO 20090201 A NO20090201 A NO 20090201A NO 20090201 L NO20090201 L NO 20090201L
Authority
NO
Norway
Prior art keywords
methods
relates
alzheimer
compositions
compounds
Prior art date
Application number
NO20090201A
Other languages
English (en)
Inventor
Daniel Sohn
Jonas Malmstrom
David Pyring
Can Slivo
Britt-Marie Swahn
David Wensbo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090201(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090201L publication Critical patent/NO20090201L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse omhandler nye heteroarylsubstituerte benzoksazolderivater og terapeutiske anvendelser for slike forbindelser, som har den strukturelle formel (Ia) under:. [Kjemisk formel skal settes inn her. Se papirkopi] og deres farmasøytisk akseptable salt, sammensetninger og fremgangsmåter for anvendelse. Dessuten omhandler oppfinnelsen nye heteroarylsubstituerte benzoksazolderivater som er egnet for avbildning av amyloide avsetninger i levende pasienter, deres sammensetninger, fremgangsmåter for anvendelse og fremgangsmåter for fremstilling av slike forbindelser. Mer spesifikt omhandler foreliggende oppfinnelse en fremgangsmåte for avbildning av amyloide avsetninger i hjerne in vivo for å tillate antemortem diagnose av Alzheimers sykdom så vel som måling av klinisk virksomhet av Alzheimers sykdom terapeutiske midler.
NO20090201A 2006-06-19 2009-01-13 Nye heteroarylsubstituerte benzoksazoler NO20090201L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81493606P 2006-06-19 2006-06-19
PCT/SE2007/000591 WO2007149030A1 (en) 2006-06-19 2007-06-18 Novel heteroaryl substituted benzoxazoles

Publications (1)

Publication Number Publication Date
NO20090201L true NO20090201L (no) 2009-01-13

Family

ID=38833677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090201A NO20090201L (no) 2006-06-19 2009-01-13 Nye heteroarylsubstituerte benzoksazoler

Country Status (16)

Country Link
US (1) US7670591B2 (no)
EP (1) EP2035418A1 (no)
JP (1) JP5548842B2 (no)
KR (1) KR20090021224A (no)
CN (1) CN101506201B (no)
AR (1) AR061515A1 (no)
AU (1) AU2007261786A1 (no)
CA (1) CA2655084A1 (no)
CL (1) CL2007001784A1 (no)
IL (1) IL195669A0 (no)
MX (1) MX2008015718A (no)
NO (1) NO20090201L (no)
TW (1) TW200813035A (no)
UY (1) UY30419A1 (no)
WO (1) WO2007149030A1 (no)
ZA (1) ZA200810163B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
AU2009260519A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
JP2012507534A (ja) * 2008-10-31 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション 新規置換アザベンゾオキサゾール類
AU2011293612B2 (en) * 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
JPWO2014132919A1 (ja) * 2013-02-28 2017-02-02 国立大学法人京都大学 診断用組成物
KR101499329B1 (ko) * 2013-06-17 2015-03-06 주식회사 대웅제약 (2-(3,4-다이메톡시페닐)-5-(3-메톡시프로필)벤조퓨란)의결정형 및 이의 제조방법
JP6149684B2 (ja) * 2013-10-21 2017-06-21 ブラザー工業株式会社 携帯端末、画像処理装置、及びプログラム
WO2015112048A1 (en) * 2014-01-24 2015-07-30 Huawei Technologies Co., Ltd. Method and device for cross-polarization interference suppression
CN104059028B (zh) * 2014-06-06 2020-10-16 北京智博高科生物技术有限公司 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用
KR101709731B1 (ko) * 2015-05-22 2017-02-23 한국과학기술연구원 벤조옥사졸 또는 벤조티아졸 화합물, 그의 제조, 및 용도
US10324943B2 (en) * 2015-08-10 2019-06-18 Business Objects Software, Ltd. Auto-monitoring and adjustment of dynamic data visualizations
CN107949383B (zh) * 2015-08-18 2022-08-23 加利福尼亚大学董事会 用于成像的含氮氧化合物的淀粉样蛋白结合剂
KR101812424B1 (ko) * 2016-12-28 2017-12-27 충북대학교 산학협력단 2-(2-아미노-5-(1-(피퍼리딘-4-일)-1H-피라졸-3-일)피리딘-3-일)벤조[d]옥사졸-6-올 및 이를 유효성분으로 포함하는 치매의 예방 및 치료용 조성물
AU2021214076A1 (en) * 2020-01-28 2022-08-04 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) * 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
JPS6394248A (ja) * 1986-10-08 1988-04-25 Canon Inc 電子写真感光体
CA2034309C (en) * 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
JPH09507071A (ja) 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
US5518713A (en) * 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
DK1334091T3 (da) 2000-08-24 2012-10-15 Univ Pittsburgh Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
ES2274973T3 (es) 2001-04-23 2007-06-01 The Trustees Of The University Of Pennsylvania Inhibidores de la agregacion de placas amiloides y agentes de obtencion de imagenes diagnosticas.
AU2002349477A1 (en) * 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
AU2003242233A1 (en) 2002-06-12 2003-12-31 Bf Research Institute, Inc. Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
EP1612204A4 (en) 2003-03-31 2007-04-11 Daiichi Seiyaku Co HYDRAZONE DERIVATIVE
DE602004016328D1 (de) 2003-05-13 2008-10-16 Hoffmann La Roche 2-imidazo-benzothiazole als adenosin-rezeptor liganden
ES2427963T3 (es) 2004-07-02 2013-11-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Uso de derivados de tioflavina radiomarcados en formación de imágenes de amiloide para evaluación de las terapias antiamiloide
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1893576A4 (en) 2005-05-27 2010-03-17 Univ Kingston TREATMENT OF PROTEIN DISORDERING
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
EP1937260A2 (en) 2005-09-16 2008-07-02 University of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
EP1945622B1 (en) 2005-10-11 2011-12-28 University of Pittsburgh - Of the Commonwealth System of Higher Education Isotopically-labeled benzofuran compounds as imagingagents for amyloidogenic proteins
EP1956013B1 (en) 2005-11-30 2016-04-13 Fujifilm RI Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
US8518980B2 (en) * 2006-02-10 2013-08-27 Summit Corporation Plc Treatment of Duchenne muscular dystrophy
US7700616B2 (en) * 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
EP2125800A1 (en) 2007-01-22 2009-12-02 AstraZeneca AB Novel heteroaryl substituted imidazo ý1,2 -a¨pyridine derivatives

Also Published As

Publication number Publication date
CA2655084A1 (en) 2007-12-27
MX2008015718A (es) 2008-12-19
CN101506201B (zh) 2012-03-14
IL195669A0 (en) 2009-09-01
KR20090021224A (ko) 2009-02-27
ZA200810163B (en) 2010-05-26
EP2035418A1 (en) 2009-03-18
CL2007001784A1 (es) 2008-01-18
AR061515A1 (es) 2008-09-03
AU2007261786A1 (en) 2007-12-27
US7670591B2 (en) 2010-03-02
JP5548842B2 (ja) 2014-07-16
WO2007149030A1 (en) 2007-12-27
JP2009541309A (ja) 2009-11-26
WO2007149030A8 (en) 2008-02-28
UY30419A1 (es) 2008-01-31
US20080027051A1 (en) 2008-01-31
TW200813035A (en) 2008-03-16
CN101506201A (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
NO20083394L (no) Nye heteroaryl substituerte benzotiasoler
WO2007149030A8 (en) Novel heteroaryl substituted benzoxazoles
WO2009155017A3 (en) Novel substituted azabenzoxazoles
UA98481C2 (en) 2-heteroaryl substituted benzothiophenes and benzofuranes
CN111039939B (zh) 用作蛋白质聚集抑制剂的杂芳基酰胺
EA021798B1 (ru) Бензоксазины, бензотиазины и родственные соединения, обладающие ингибирующей nos активностью
NO20071583L (no) Diagnostisk middel for tumor
NO330176B1 (no) Amyloidbindende forbindelse, fremgangsmater for fremstilling og anvendelse derav, farmasoytisk sammensetning for in vivo-avbilding og anvendelse derav
DK2968385T3 (en) URIDINNUCLEOSIDE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR USING THEREOF
NO20092293L (no) Sulfonyl-fenyl-2H-[1,2,4]oksodiazol-5-onderivater, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytiske midler
WO2011123719A2 (en) Use of faah inhibitors for treating abdominal, visceral and pelvic pain
AU2012315671B2 (en) Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
BR112017011555B1 (pt) Formulação farmacêutica compreendendo 2-((1-(2(4- fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1- ona e kit
WO2012037105A1 (en) Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
EA201100267A1 (ru) Новые бензофураны, подходящие в качестве предшественников соединений, которые являются полезными для визуализации амилоидных отложений
WO2010051196A8 (en) Novel substituted azabenzoxazoles
JP6023926B2 (ja) 認知症治療のための５−ｈｔ４受容体アゴニスト
MX2009009113A (es) Nuevos indoles 2-heteroaril sustituidos 695.
ES2672777T3 (es) Métodos de tratamiento de estados con mediación alfa-adrenérgica
TWI441634B (zh) 4-（1-羥基-1-甲基乙基）-2-丙基-1-〔4-〔2-（四唑-5-基）苯基〕苯基〕甲基咪唑-5-羧酸、其藥理容許鹽或其藥理容許酯之用途
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
JP2022046536A (ja) ビスホスホネートの骨格除去
WO2006020156A3 (en) Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer’s disease
KR102292894B1 (ko) 신규한 갑상선 호르몬 유도체 및 이의 용도

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application